PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30083256-0	2018	Blocking CDK1/PDK1/beta-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma.	RO 3306	60-66	cyclin dependent kinase 1	Homo sapiens	9-13	
30083256-0	2018	Blocking CDK1/PDK1/beta-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma.	RO 3306	60-66	cyclin dependent kinase 1	Homo sapiens	45-49	
30083256-7	2018	CDK1 inhibitor RO3306 in combination with sorafenib treatment significantly decreased tumor growth in PDX tumor models.	RO 3306	15-21	cyclin dependent kinase 1	Homo sapiens	0-4	
30083256-12	2018	Mechanistic and functional studies silencing CDK1 with shRNA and RO3306 combined with sorafenib abolished oncogenic function via downregulating CDK1, with downstream PDK1 and beta-Catenin inactivation.	RO 3306	65-71	cyclin dependent kinase 1	Homo sapiens	45-49	
30083256-12	2018	Mechanistic and functional studies silencing CDK1 with shRNA and RO3306 combined with sorafenib abolished oncogenic function via downregulating CDK1, with downstream PDK1 and beta-Catenin inactivation.	RO 3306	65-71	cyclin dependent kinase 1	Homo sapiens	144-148